Rosetta Genomics Ltd
OTC:ROSGQ
Net Margin
Rosetta Genomics Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | IL |
| Market Cap | 29.6k USD |
| Net Margin |
-230%
|
| Country | US |
| Market Cap | 289.2B USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 171.1B USD |
| Net Margin |
13%
|
| Country | US |
| Market Cap | 112.7B USD |
| Net Margin |
37%
|
| Country | US |
| Market Cap | 107.8B USD |
| Net Margin |
29%
|
| Country | AU |
| Market Cap | 136.7B AUD |
| Net Margin |
17%
|
| Country | US |
| Market Cap | 83.5B USD |
| Net Margin |
2%
|
| Country | US |
| Market Cap | 49.4B USD |
| Net Margin |
-116%
|
| Country | US |
| Market Cap | 43.1B USD |
| Net Margin |
-33%
|
| Country | US |
| Market Cap | 34.3B USD |
| Net Margin |
12%
|
| Country | KR |
| Market Cap | 39.6T KRW |
| Net Margin |
25%
|
Profitability Report
View the profitability report to see the full profitability analysis for Rosetta Genomics Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Rosetta Genomics Ltd's most recent financial statements, the company has Net Margin of -229.8%.
You don't have any saved screeners yet
